195 related articles for article (PubMed ID: 35279626)
1. Diagnosing 'transition' to secondary progressive multiple sclerosis (SPMS): A step-by-step approach for clinicians.
Hamdy E; Talaat F; Ramadan I; Marouf H; Hamdy MM; Sadallah H; El-Ashmawy GAH; Elsalamawy D; Said SM
Mult Scler Relat Disord; 2022 Apr; 60():103718. PubMed ID: 35279626
[TBL] [Abstract][Full Text] [Related]
2. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
Boyko A; Therapontos C; Horakova D; Szilasiová J; Kalniņa J; Kolontareva J; Gross-Paju K; Selmaj K; Sereike I; Milo R; Gabelić T; Rot U
Mult Scler Relat Disord; 2021 May; 50():102778. PubMed ID: 33592384
[TBL] [Abstract][Full Text] [Related]
3. Results from SPECTRUM: A survey of healthcare professionals to understand current diagnosis and management practices for secondary progressive multiple sclerosis in the United Kingdom.
Duddy M; Wilkinson C; Medhurst S; Rhys K
Mult Scler Relat Disord; 2021 Oct; 55():103174. PubMed ID: 34399317
[TBL] [Abstract][Full Text] [Related]
4. Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey.
Alvarez E; Nair KV; Gorritz M; Bartolome L; Maloney H; Ding Y; Golan T; Wade RL; Kumar R; Su W; Shah R; Russo P
Mult Scler Relat Disord; 2021 May; 50():102858. PubMed ID: 33799068
[TBL] [Abstract][Full Text] [Related]
5. Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.
Kopp TI; Bramow S; Illes Z; Kant M; Kristensen C; Rasmussen PV; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2021 Nov; 56():103319. PubMed ID: 34666241
[TBL] [Abstract][Full Text] [Related]
6. A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.
Inojosa H; Proschmann U; Akgün K; Ziemssen T
J Neurol; 2021 Apr; 268(4):1210-1221. PubMed ID: 31363847
[TBL] [Abstract][Full Text] [Related]
7. Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis.
Maier S; Barcutean L; Andone S; Manu D; Sarmasan E; Bajko Z; Balasa R
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901807
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis.
Katz Sand I; Krieger S; Farrell C; Miller AE
Mult Scler; 2014 Oct; 20(12):1654-7. PubMed ID: 24493475
[TBL] [Abstract][Full Text] [Related]
9. A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views.
Ziemssen T; Tolley C; Bennett B; Kilgariff S; Jones E; Pike J; Tomic D; Piani-Meier D; Lahoz R
Mult Scler Relat Disord; 2020 Feb; 38():101861. PubMed ID: 31865132
[TBL] [Abstract][Full Text] [Related]
10. Discussing the potential for progression with patients newly diagnosed with multiple sclerosis: When, how, and why?
Shosha E; Burton JM
Mult Scler Relat Disord; 2022 Dec; 68():104230. PubMed ID: 36240704
[TBL] [Abstract][Full Text] [Related]
11. Living with secondary progressive multiple sclerosis in Europe: perspectives of multiple stakeholders.
Torkildsen Ø; Linker RA; Sesmero JM; Fantaccini S; Sanchez-de la Rosa R; Seze J; Duddy M; Chan A
Neurodegener Dis Manag; 2021 Feb; 11(1):9-19. PubMed ID: 33234006
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis.
Tedeholm H; Piehl F; Lycke J; Link J; Stawiarz L; Burman J; de Flon P; Fink K; Gunnarsson M; Mellergård J; Nilsson P; Sundström P; Svenningsson A; Johansson H; Andersen O
Mult Scler Relat Disord; 2022 Dec; 68():104220. PubMed ID: 36242804
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina.
Rojas JI; Patrucco L; Alonso R; Garcea O; Deri N; Carnero Contentti E; Lopez PA; Pettinicchi JP; Caride A; Cristiano E
Mult Scler; 2021 Apr; 27(4):579-584. PubMed ID: 32484381
[TBL] [Abstract][Full Text] [Related]
14. Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
Kizlaitienė R; Kaubrys G; Giedraitienė N; Ramanauskas N; Dementavičienė J
Med Sci Monit; 2017 Feb; 23():588-597. PubMed ID: 28145395
[TBL] [Abstract][Full Text] [Related]
15. The uncertainty period preceding the clinical defined SPMS diagnosis and the applicability of objective classifiers - A Danish single center study.
Holm RP; Pontieri L; Wandall-Holm MF; Framke E; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2023 Mar; 71():104546. PubMed ID: 36764284
[TBL] [Abstract][Full Text] [Related]
16. Difficulty in identification of patients with active secondary progressive multiple sclerosis by clinical classification tools.
Klinsing S; Yalachkov Y; Foerch C
Eur J Neurol; 2022 Apr; 29(4):1100-1105. PubMed ID: 34939266
[TBL] [Abstract][Full Text] [Related]
17. How to measure the treatment response in progressive multiple sclerosis: Current perspectives and limitations in clinical settings'.
Lorefice L; Mellino P; Fenu G; Cocco E
Mult Scler Relat Disord; 2023 Aug; 76():104826. PubMed ID: 37327601
[TBL] [Abstract][Full Text] [Related]
18. Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.
Lizak N; Malpas CB; Sharmin S; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Lugaresi A; Duquette P; Girard M; Prat A; Larochelle C; Trojano M; Grand'Maison F; Grammond P; Sola P; Ferraro D; Hupperts R; Bergamaschi R; Boz C; Van Pesch V; Spitaleri D; Terzi M; Kalincik T;
JAMA Neurol; 2020 Nov; 77(11):1398-1407. PubMed ID: 32716480
[TBL] [Abstract][Full Text] [Related]
19. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
[TBL] [Abstract][Full Text] [Related]
20. The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals.
O'Loughlin E; Hourihan S; Chataway J; Playford ED; Riazi A
Disabil Rehabil; 2017 Sep; 39(18):1821-1828. PubMed ID: 27685028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
